ZDHHC13

Summary

ZDHHC13 (zDHHC palmitoyltransferase 13, HGNC:18413) is a protein-coding gene on chromosome 11p15.1, encoding Palmitoyltransferase ZDHHC13 (Q8IUH4). Palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates.

Predicted to enable magnesium ion transmembrane transporter activity and palmitoyltransferase activity. Involved in positive regulation of canonical NF-kappaB signal transduction. Located in endoplasmic reticulum.

Source: NCBI Gene 54503 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 96 total
• MANE Select transcript: NM_019028

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18413
Approved symbol	ZDHHC13
Name	zDHHC palmitoyltransferase 13
Location	11p15.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10852, FLJ10941, HIP14L
Ensembl gene	ENSG00000177054
Ensembl biotype	protein_coding
OMIM	612815
Entrez	54503

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 5 protein_coding, 4 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000399351, ENST00000446113, ENST00000524744, ENST00000525490, ENST00000530100, ENST00000530698, ENST00000532026, ENST00000532812, ENST00000862732, ENST00000862733, ENST00000931681

RefSeq mRNA: 2 — MANE Select: NM_019028 NM_001001483, NM_019028

CCDS: CCDS44550, CCDS44551

Canonical transcript exons

ENST00000446113 — 17 exons

Exon	Start	End
ENSE00001411114	19170411	19170568
ENSE00001419622	19166302	19166385
ENSE00002148400	19175822	19176415
ENSE00002156419	19117168	19117276
ENSE00003478783	19142978	19143123
ENSE00003514057	19152559	19152684
ENSE00003525457	19155796	19155929
ENSE00003544925	19150727	19150791
ENSE00003559170	19158940	19159040
ENSE00003594947	19152158	19152320
ENSE00003605738	19163303	19163427
ENSE00003644328	19164301	19164363
ENSE00003650308	19165052	19165145
ENSE00003677587	19146181	19146303
ENSE00003689282	19147596	19147673
ENSE00003689489	19149187	19149331
ENSE00003694317	19172723	19172820

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 95.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.1056 / max 89.2489, expressed in 1782 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
113359	10.7974	1775
113360	1.3082	667

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	95.92	gold quality
epithelium of nasopharynx	UBERON:0001951	95.30	gold quality
lower esophagus mucosa	UBERON:0035834	94.53	gold quality
pharyngeal mucosa	UBERON:0000355	93.69	gold quality
tongue squamous epithelium	UBERON:0006919	93.67	gold quality
esophagus mucosa	UBERON:0002469	93.22	gold quality
oral cavity	UBERON:0000167	92.94	gold quality
bronchial epithelial cell	CL:0002328	92.84	gold quality
ventricular zone	UBERON:0003053	92.61	gold quality
sperm	CL:0000019	92.33	gold quality
esophagus squamous epithelium	UBERON:0006920	91.89	gold quality
palpebral conjunctiva	UBERON:0001812	91.86	gold quality
epithelium of esophagus	UBERON:0001976	91.34	gold quality
epithelium of bronchus	UBERON:0002031	91.18	gold quality
bronchus	UBERON:0002185	90.50	gold quality
squamous epithelium	UBERON:0006914	90.24	gold quality
rectum	UBERON:0001052	89.90	gold quality
nasal cavity epithelium	UBERON:0005384	89.64	gold quality
male germ cell	CL:0000015	89.50	gold quality
gingival epithelium	UBERON:0001949	89.20	gold quality
gingiva	UBERON:0001828	88.66	gold quality
ganglionic eminence	UBERON:0004023	88.47	gold quality
nasal cavity mucosa	UBERON:0001826	88.43	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	88.15	gold quality
adrenal tissue	UBERON:0018303	88.02	gold quality
skin of abdomen	UBERON:0001416	87.73	gold quality
secondary oocyte	CL:0000655	87.67	gold quality
islet of Langerhans	UBERON:0000006	87.62	gold quality
mucosa of paranasal sinus	UBERON:0005030	87.60	gold quality
oviduct epithelium	UBERON:0004804	87.55	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.78

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting ZDHHC13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-5580-3P	99.70	69.41	2052
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-578	99.46	68.36	1787
HSA-MIR-7151-5P	99.37	67.82	613
HSA-MIR-135A-5P	99.36	71.85	1601
HSA-MIR-135B-5P	99.36	71.63	1613
HSA-MIR-6882-5P	99.35	71.13	1206
HSA-MIR-6507-3P	99.35	67.32	1059
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-138-2-3P	98.91	68.33	1643
HSA-MIR-374A-3P	98.87	67.82	1531

Literature-anchored findings (GeneRIF, showing 5)

• huntingtin interacting protein genes, HIP14 and HIP14L, encode Mg2+ transport proteins that are regulated by their innate palmitoyl acyltransferases thus fulfilling the characteristics of “chanzymes.” (PMID:18794299)
• Data show that deletion of huntingtin protein (HTT) amino acids 1-427 abolishes the interaction of HTT with palmitoyl acyltransferases huntingtin interacting protein 14 (HIP14) and huntingtin interacting protein 14-like (HIP14L). (PMID:24651384)
• This suggests that altered HIP14-HTT and HIP14L-HTT interactions in the presence of the HD mutation reduces palmitoylation and promotes mislocalization of HTT and other HIP14/HIP14L substrates (PMID:25849918)
• this is the first study to demonstrate that defects in ZDHHC13, a PAT, leads to phenotypes in mice, including non-thyroidal hypermetabolism, mitochondrial dysfunction, and abnormal lipid metabolism. (PMID:28526873)
• AMPK Phosphorylates ZDHHC13 to Increase MC1R Activity and Suppress Melanomagenesis. (PMID:36701140)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zdhhc13	ENSDARG00000101144
mus_musculus	Zdhhc13	ENSMUSG00000030471
rattus_norvegicus	Zdhhc13	ENSRNOG00000014277
drosophila_melanogaster	Hip14	FBGN0259824

Paralogs (2): ZDHHC17 (ENSG00000186908), ANKRD35 (ENSG00000198483)

Protein

Protein identifiers

Palmitoyltransferase ZDHHC13 — Q8IUH4 (reviewed: Q8IUH4)

Alternative names: Huntingtin-interacting protein 14-related protein, Huntingtin-interacting protein HIP3RP, Putative MAPK-activating protein PM03, Putative NF-kappa-B-activating protein 209, Zinc finger DHHC domain-containing protein 13

All UniProt accessions (1): Q8IUH4

UniProt curated annotations — full annotation on UniProt →

Function. Palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates. Palmitoyltransferase for HTT and GAD2. May play a role in Mg(2+) transport.

Subunit / interactions. Interacts (via ANK repeats) with CLIP3. Interacts (via ANK repeats) with DNAJC5 (via C-terminus). Interacts (via ANK repeats) with HTT. Interacts (via ANK repeats) with MAP6. Interacts (via ANK repeats) with SNAP23. Interacts (via ANK repeats) with SNAP25. May interact (via ANK repeats) with SPRED2.

Subcellular location. Golgi apparatus membrane. Cytoplasmic vesicle membrane.

Domain organisation. The DHHC domain is required for palmitoyltransferase activity.

Similarity. Belongs to the DHHC palmitoyltransferase family. AKR/ZDHHC17 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8IUH4-1	1	yes
Q8IUH4-2	2
Q8IUH4-3	3

RefSeq proteins (2): NP_001001483, NP_061901* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001594	Palmitoyltrfase_DHHC	Domain
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily

Pfam: PF01529, PF12796

Catalyzed reactions (Rhea), 1 shown:

• L-cysteinyl-[protein] + hexadecanoyl-CoA = S-hexadecanoyl-L-cysteinyl-[protein] + CoA (RHEA:36683)

UniProt features (30 total): topological domain 7, repeat 7, transmembrane region 6, splice variant 2, sequence variant 2, sequence conflict 2, chain 1, domain 1, active site 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IUH4-F1	87.71	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 456 (s-palmitoyl cysteine intermediate)

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 127 (showing top): GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_MAGNESIUM_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, DOANE_RESPONSE_TO_ANDROGEN_DN, GOCC_GOLGI_ASSOCIATED_VESICLE, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, HOOI_ST7_TARGETS_DN, GOBP_POSITIVE_REGULATION_OF_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_TRANSMEMBRANE_TRANSPORT, SENESE_HDAC3_TARGETS_DN, NUYTTEN_EZH2_TARGETS_DN, GOCC_GOLGI_ASSOCIATED_VESICLE_MEMBRANE, MULLIGHAN_MLL_SIGNATURE_1_UP, GOMF_S_ACYLTRANSFERASE_ACTIVITY

GO Biological Process (2): positive regulation of canonical NF-kappaB signal transduction (GO:0043123), magnesium ion transmembrane transport (GO:1903830)

GO Molecular Function (6): magnesium ion transmembrane transporter activity (GO:0015095), palmitoyltransferase activity (GO:0016409), protein-cysteine S-palmitoyltransferase activity (GO:0019706), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (7): Golgi membrane (GO:0000139), endoplasmic reticulum (GO:0005783), membrane (GO:0016020), Golgi-associated vesicle membrane (GO:0030660), Golgi apparatus (GO:0005794), cytoplasmic vesicle membrane (GO:0030659), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
bounding membrane of organelle	2
endomembrane system	2
intracellular membrane-bounded organelle	2
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
magnesium ion transport	1
monoatomic cation transmembrane transport	1
metal ion transmembrane transporter activity	1
magnesium ion transmembrane transport	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
palmitoyltransferase activity	1
protein-cysteine S-acyltransferase activity	1
binding	1
catalytic activity	1
transferase activity	1
Golgi apparatus	1
cellular anatomical structure	1
Golgi-associated vesicle	1
cytoplasmic vesicle membrane	1
vesicle membrane	1
cytoplasmic vesicle	1
intracellular vesicle	1

Protein interactions and networks

STRING

750 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZDHHC13	HTT	P42858	881
ZDHHC13	SNAP25	P13795	833
ZDHHC13	PALM	O75781	832
ZDHHC13	ZDHHC6	Q9H6R6	697
ZDHHC13	SYT7	O43581	689
ZDHHC13	ZDHHC22	Q8N966	686
ZDHHC13	ZDHHC8	Q9ULC8	650
ZDHHC13	ZDHHC11	Q9H8X9	639
ZDHHC13	ZDHHC1	Q8WTX9	634
ZDHHC13	ZDHHC3	Q9NYG2	614
ZDHHC13	PPT1	P50897	589
ZDHHC13	SNAP23	O00161	579
ZDHHC13	DLG4	P78352	564
ZDHHC13	PPT2	Q9UMR5	538
ZDHHC13	SYT1	P21579	533

IntAct

68 interactions, top by confidence:

A	B	Type	Score
B3GAT3	GOLIM4	psi-mi:“MI:0914”(association)	0.640
IPPK	TMEM223	psi-mi:“MI:0914”(association)	0.530
C3AR1	TMEM120B	psi-mi:“MI:0914”(association)	0.530
SPINT2	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
CD83	BTAF1	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM120B	psi-mi:“MI:0914”(association)	0.530
MRAP2	GOLIM4	psi-mi:“MI:0914”(association)	0.530
WBP1	EXTL3	psi-mi:“MI:0914”(association)	0.530
TMEM9	ESYT2	psi-mi:“MI:0914”(association)	0.530
FANCD2OS	CNOT1	psi-mi:“MI:0914”(association)	0.530
KCNE3	RIOK3	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
MRAP2	GOSR1	psi-mi:“MI:0914”(association)	0.350
WBP1	HSPA12A	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
rep	B4GALT3	psi-mi:“MI:0914”(association)	0.350
TSPAN15	TMEM223	psi-mi:“MI:0914”(association)	0.350
GPR17	TMEM120B	psi-mi:“MI:0914”(association)	0.350
KRTCAP3	SLC22A23	psi-mi:“MI:0914”(association)	0.350
CRLF2	METTL15	psi-mi:“MI:0914”(association)	0.350
DGCR2	CCDC85C	psi-mi:“MI:0914”(association)	0.350
RNF149	CCDC85C	psi-mi:“MI:0914”(association)	0.350
PLAC8L1	A2ML1	psi-mi:“MI:0914”(association)	0.350
DNAJC5	HIDE1	psi-mi:“MI:0914”(association)	0.350
CX3CL1	FAM171A2	psi-mi:“MI:0914”(association)	0.350
SCAP	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
CCR6	GPR89A	psi-mi:“MI:0914”(association)	0.350

BioGRID (88): ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Affinity Capture-RNA), ZDHHC13 (Proximity Label-MS), ZDHHC13 (Proximity Label-MS), ZDHHC13 (Affinity Capture-MS), ZDHHC13 (Proximity Label-MS), ZDHHC13 (Proximity Label-MS), ZDHHC13 (Proximity Label-MS)

ESM2 similar proteins: A0A077K8G3, A0A077K9K6, A0A0B4ZTQ2, A0A0B5A051, A0A0B5L778, A0A0U5CJV1, A0A1Y0BRF7, A0A3G9GNJ4, A0A455LLV4, A0A455ZJC3, A0A8D5M7V9, B9A1Q4, D3ZS74, E5RP65, F1DBA7, F4IQV7, F4JPW1, G0LET6, G1XTZ7, G3Y418, G5DBJ0, O22780, O80899, P9WEQ7, P9WEW7, P9WEX2, Q09701, Q0C8A6, Q2N2K0, Q3KQJ0, Q3SZN3, Q4R690, Q4WBI5, Q5AR21, Q5NVB9, Q67YT8, Q67ZM7, Q8IUH4, Q8TFH4, Q8VY13

Diamond homologs: A0A0R4IDP3, A2CEX1, A2VEY9, A5WVX9, B3DN87, C8VCL4, E1BLT8, E7F021, E7F587, E7FBS9, E7FH11, E9PTT0, E9QCD3, F1Q7H8, F1QAM1, F1QHM7, F1QX91, F1QXD3, F1R013, F1RE57, J9VJ99, O60069, O74384, O80685, P42836, P59267, P59268, Q04629, Q0VC89, Q10L01, Q2TGJ1, Q2TGJ4, Q2TGK3, Q2THW7, Q2THW8, Q2THW9, Q2THX0, Q2THX1, Q4R690, Q4WZL8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ATR	“up-regulates activity”	ZDHHC13	phosphorylation
ZDHHC13	“up-regulates activity”	MC1R	palmitoylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 99 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Class A/1 (Rhodopsin-like receptors)	7	8.4×	4e-03
G alpha (i) signalling events	9	5.7×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5	12.7×	9e-03
positive regulation of cytosolic calcium ion concentration	8	10.9×	4e-04
adenylate cyclase-activating G protein-coupled receptor signaling pathway	7	9.2×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

96 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	70
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2466 predictions. Top by Δscore:

Variant	Effect	Δscore
11:19143123:AG:A	donor_loss	1.0000
11:19143124:G:A	donor_loss	1.0000
11:19143124:G:GG	donor_gain	1.0000
11:19143125:TA:T	donor_loss	1.0000
11:19143126:AA:A	donor_loss	1.0000
11:19146177:T:TA	acceptor_gain	1.0000
11:19146179:A:AG	acceptor_gain	1.0000
11:19146180:G:GG	acceptor_gain	1.0000
11:19146183:AC:A	acceptor_gain	1.0000
11:19146299:GTAAA:G	donor_gain	1.0000
11:19146303:AGTAA:A	donor_loss	1.0000
11:19146304:G:C	donor_loss	1.0000
11:19146304:G:GG	donor_gain	1.0000
11:19147669:ATCCG:A	donor_loss	1.0000
11:19147670:TCCGG:T	donor_loss	1.0000
11:19147671:CCGGT:C	donor_loss	1.0000
11:19147672:CGG:C	donor_loss	1.0000
11:19147674:G:T	donor_loss	1.0000
11:19147675:T:C	donor_loss	1.0000
11:19149185:A:AG	acceptor_gain	1.0000
11:19149186:G:GG	acceptor_gain	1.0000
11:19149186:GACAA:G	acceptor_gain	1.0000
11:19149328:ACAGG:A	donor_loss	1.0000
11:19149330:AGGTA:A	donor_loss	1.0000
11:19149331:GGTA:G	donor_loss	1.0000
11:19149333:T:A	donor_loss	1.0000
11:19150725:A:AG	acceptor_gain	1.0000
11:19150726:G:GG	acceptor_gain	1.0000
11:19150726:GA:G	acceptor_gain	1.0000
11:19150726:GAGT:G	acceptor_gain	1.0000

AlphaMissense

4108 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:19146269:T:A	W88R	1.000
11:19146269:T:C	W88R	1.000
11:19146271:G:C	W88C	1.000
11:19146271:G:T	W88C	1.000
11:19146202:T:G	C65W	0.999
11:19146270:G:C	W88S	0.999
11:19146272:G:C	A89P	0.999
11:19146275:G:C	A90P	0.999
11:19146276:C:A	A90D	0.999
11:19147648:T:C	S117P	0.999
11:19147655:C:A	P119H	0.999
11:19147663:T:A	W122R	0.999
11:19147663:T:C	W122R	0.999
11:19147665:G:C	W122C	0.999
11:19147665:G:T	W122C	0.999
11:19147666:G:C	A123P	0.999
11:19147673:G:C	R125P	0.999
11:19149216:T:C	L135S	0.999
11:19149315:T:C	L168P	0.999
11:19146181:A:C	Q58H	0.998
11:19146181:A:T	Q58H	0.998
11:19146200:T:C	C65R	0.998
11:19146201:G:A	C65Y	0.998
11:19146231:T:A	V75D	0.998
11:19146264:T:A	L86H	0.998
11:19146273:C:A	A89D	0.998
11:19146279:T:A	I91N	0.998
11:19147655:C:G	P119R	0.998
11:19147658:T:C	L120P	0.998
11:19147667:C:A	A123D	0.998

dbSNP variants (sampled 300 via entrez): RS1000128709 (11:19142796 G>A,C), RS1000131588 (11:19138152 T>A,C), RS1000241728 (11:19133159 T>G), RS1000273436 (11:19162376 C>T), RS1000295298 (11:19143877 C>A), RS1000385384 (11:19156867 C>G), RS1000449711 (11:19137565 A>G), RS1000540321 (11:19163710 A>G), RS1000563317 (11:19122443 C>T), RS1000622222 (11:19134162 T>C), RS1000661933 (11:19175463 A>C,G,T), RS1000688865 (11:19170930 A>G), RS1000736393 (11:19170409 A>C), RS1000763890 (11:19163374 A>T), RS1000797494 (11:19134564 G>A)

Disease associations

OMIM: gene MIM:612815 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	increases abundance, increases expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	increases expression	1
Nickel	decreases expression	1
Polychlorinated Biphenyls	affects expression	1
Silicon Dioxide	increases expression	1
Dronabinol	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	decreases expression	1
Sodium Selenite	decreases expression	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	increases expression	1
Lactic Acid	decreases expression	1

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7HU	Ubigene HEK293T ZDHHC13 KO	Transformed cell line	Female
CVCL_TY68	HAP1 ZDHHC13 (-) 1	Cancer cell line	Male
CVCL_TY69	HAP1 ZDHHC13 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.